Literature DB >> 12168078

Expression of collagen type II, S100B, S100A2 and osteocalcin in chondroblastoma and chondromyxoid fibroma.

Hye-Rim Park1, Yong-Koo Park, Kee Taek Jang, K Krishnan Unni.   

Abstract

Chondroblastoma and chondromyxoid fibroma (CMF) has been investigated in numerous histological studies, but its biological nature and histogenetic origin are still a matter of debate. We evaluated the expression of type II collagen, S100A2, S100B, and osteocalcin to study the matrix biochemistry and phenotype of the neoplastic cells in these tumors. Immunohistochemically, the expression of type II collagen was diffuse in 15 cases (75%) among total 20 chondroblastomas and 12 (85.7%) among total 14 CMFs. The expression of S100B was also diffuse in all cases (100%) of chondroblastomas and 12 cases (85.7%) of CMFs. We were able to obtain the expression of S100A2, focally. The expression of osteocalcin was focally noted in 18 cases (90%) of chondroblastomas and 8 cases (57.1%) of CMFs. In conclusion, our data support that chondroblastoma and CMF are a distinct tumor entity with the basic expression of chondroid markers. But these tumors also show histologic diversity with focal co-expression of osteoid markers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12168078

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  3 in total

Review 1.  The application of immunohistochemistry in the diagnosis of bone tumors and tumor-like lesions.

Authors:  Zhenqiang Gao; Leonard B Kahn
Journal:  Skeletal Radiol       Date:  2005-09-28       Impact factor: 2.199

Review 2.  S100 protein family in human cancer.

Authors:  Hongyan Chen; Chengshan Xu; Qing'e Jin; Zhihua Liu
Journal:  Am J Cancer Res       Date:  2014-03-01       Impact factor: 6.166

3.  Chondromyxoid fibroma of rib with a novel chromosomal translocation: a report of four additional cases at unusual sites.

Authors:  Henry B Armah; Richard L McGough; Mark A Goodman; Susanne M Gollin; Urvashi Surti; Anil V Parwani; Uma N M Rao
Journal:  Diagn Pathol       Date:  2007-11-24       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.